RQ Bio raised $115 million in a Series A led by Frazier Life Sciences to advance RQB01, a preclinical long-acting antibody program intended to provide season-long prevention of seasonal influenza. The company claims RQB01 targets conserved viral features and is designed for durable protective effects from a single dose. RQ Bio said the differentiated dual mechanism aims to reduce sensitivity to antigenic drift across strains, with the program in IND-enabling studies. The funding round also names Christian Schade as executive chairman, linking the company to leadership with prior clinical development experience. The financing reinforces investor demand for next-generation respiratory prophylaxis beyond annual vaccines, particularly for high-risk populations where protection reliability and access can be variable. For competitors, the round raises the bar for long-lasting delivery and breadth claims in seasonal influenza prophylaxis programs.